Medarex, Inc. (MEDX : NASDAQ)
06/14/00 07:39 AM EDT
Reuters
Back to Headlines | Show All News
06/13/00 15:47 Medarex and MedImmune to develop human antibodies
GAITHERSBURG, Md., June 13 (Reuters) - Biotechnology
company MedImmune Inc. (MEDI.O) said Tuesday it has signed an
agreement with Medarex Inc. (MEDX.O) to develop fully human
antibodies to multiple antigens using Medarex's technology.
Under the terms of the deal, MedImmune receives an
exclusive license for the use of Medarex's HuMAb-Mouse
technology for the development of antibodies against
respiratory syncytial virus and an option to further license
the use of this technology for additional antigens.
Princeton, N.J.-based Medarex, a biopharmaceutical
developer, will receive technology access fees and could
receive license and milestone payments, as well as royalties on
product sales.
Earlier this month, Medarex entered into an alliance with
Biosite Diagnostics Inc. (BSTE.O) combining Medarex's
HuMAb-Mouse technology with Biosite's Omniclonal phage display
technology to offer drug and biotechnology companies access to
volumes of human antibodies to validate genomic targets and to
identify promising drug candidates.
Medarex's HuMAb-Mouse technology enables the creation of
fully human antibodies, meaning that mouse genes for creating
antibodies have been replaced by human antibody genes.
Shares of Medarex were up 3-3/8 at 82-1/2, and MedImmune
was trading up 3-7/16 at 65-3/4.
Gruß,
kalahari
